Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI-9305A
- Development stage
- Preclinical
- Lead developer
- Beta Pharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
BPI-9305A is an antibody-drug conjugate (ADC) being developed by Beta Pharma for the treatment of solid tumors. As an ADC, it is designed to combine the targeting specificity of a monoclonal antibody with the cell-killing potency of a cytotoxic payload. The drug is part of Beta Pharma's oncology pipeline, which includes a series of ADC candidates (BPI-9302A through BPI-9305A) aimed at various solid malignancies. While the specific molecular target, linker technology, and payload for BPI-9305A have not been publicly disclosed, the candidate represents the company's strategic focus on next-generation targeted therapies in the oncology space.
Beyond the preview
Go deeper on BPI-9305A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BPI-9305A.